Muscle & Nerve · 2009 · 35 citations · 28 references
Life SciencesImmunologyPathologyAutoimmunityClinical ImmunologyImmunopathologyAutoantibodiesAutoimmune Disease DiagnosticsAutoimmune Disease PathologyAutoimmune DiseasesComplement DisordersMyasthenia GravisAnti-acetylcholine Receptor AntibodiesC3 Complement LevelsClinical Severity ClassificationClinical Severity ScoringComplement In Autoimmune DiseaseImmunological MechanismsQuantitative Myasthenia Gravis Score
Acute exacerbation of generalized myasthenia gravis (GMG) can cause swallowing impairment, respiratory failure, or death. It is important to identify immunological factors that might be regarded reliably as an index of the patient's clinical condition, response to treatment, and measure of certain immune aberrations of MG. In this study we investigated correlations between complement component C3, acetylcholine receptor antibody (AChRab) titer, and clinical severity of GMG. AChRab titer and C3 concentration were determined by radioimmunoassay and nephelometry, respectively. The clinical severity of GMG was assessed by the quantitative MG score (QMGS) according to Besinger and colleagues. Our findings indicate that the C3 level correlates with clinical severity of AChRab-positive GMG.
28
Antibody to acetylcholine receptor in myasthenia gravis
Jon Lindstrom, Marjorie E. Seybold, Vanda A. Lennon et al. · Neurology · 1976 · 1.2K citations · Full text
Life Sciences, Immunology, Neurology +12
Milan Bašta, Marinos C. Dalakas · Journal of Clinical Investigation · 1994 · 395 citations · Full text
Life Sciences, Immunology, Pathology +17
U. A. Besinger, Klaus V. Toyka, Martina Hömberg et al. · Neurology · 1983 · 275 citations
Life Sciences, Immunology, Neurology +17